Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

NOVEMBER 23, 2021

COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Building the Data Backend. CannabisFN.com and CFN Media, have been hired to create awareness. Mental Health Challenges.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Media: Liz Melone.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JUNE 7, 2021

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Media Contact: Will Johnson. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. About FTSE Russell.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? The cannabis research problem.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Cannabis Law Report

JULY 8, 2021

The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. and are difficult to predict. cbdMD, Inc. John Weston. Director of Investor Relations.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Miss Marijuana

JUNE 30, 2019

I mean duh, with social media, bosses that don’t understand you have a life and the new Bob Dylan documentary on Netflix – how can anyone doze off and dream anymore? And who doesn’t feel that dark cloud of stress, anxiety and drag get bigger when they’re tossing and turning all night? Our health and wellness depends on it!

Sleep 72

Sleep CBD Clinical Trials Oil 72

Cannabis Law Report

JANUARY 6, 2022

He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. Anderson will be responsible for Anebulo’s global investor relations and public relations programs.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Media Enquiries: Sam Brown Inc. media enquiries.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. March 31, 2021. ($). .

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Some of the more interesting data on the relationship between opioids and medical marijuana for pain management comes from the field of orthopedic surgery. million to 11.4

Marijuana 88

Marijuana Patients Clinical Trials Data 88

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”. Media: Liz Melone. 212-362-1200.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

The Blunt Truth

AUGUST 13, 2019

To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.”. The FDA is collecting data to fill these gaps. The FDA cautioned that, without prompt action, legal action may follow, including seizure and injunctions.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

NOVEMBER 10, 2021

Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs. Media: Laura Radocaj. About Virpax Pharmaceuticals. Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597. Betsy Brod. Affinity Growth Advisors. 212-825-3210.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

SEPTEMBER 24, 2019

The approval of cannabidiol oral solution is based on results from four randomised, controlled Phase 3 trials. These studies incorporate data from more than 714 patients with either LGS or Dravet syndrome, two rare forms of epilepsy with high morbidity and mortality rates, which place a significant burden on families and caregivers. “The

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 12, 2019

The opening of private cannabis clinics in the UK is in response to the British Home Office making medicinal cannabis legal from 1 November 2018, reclassifying it from Schedule 1 to Schedule 2 under the 2001 Misuse of Drugs Regulations. The new legislation permits specialist doctors to legally prescribe cannabis-based medicines.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

JULY 23, 2019

It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. Some states require mandatory warning statements in advertisements for medical cannabis. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Cannabis Law Report

JULY 24, 2019

1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products. Anxiety, depression, post-traumatic stress disorders, and even schizophrenia.

CBD 51

CBD Tincture Pets Chronic Pain 51

The Cannigma

APRIL 8, 2021

CP: I’m going to say yes and it’s hard to tie this together, but there’s actually some really good animal, and a little bit of human data to support this. I postulate that that is correlated to our endocannabinoid system, which good data is now suggesting, is dysregulated in metabolic syndrome: obesity, diabetes, heart disease.

Medicine 112

Medicine Cannabinoids Cannabis THC 112

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. Media Contact: media@mindmed.co.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. For more information, please contact the Company at: Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. At the same time, the outlook on cannabis research data is largely positive. Media framing of cannabis. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Established history of providing ketamine infusion services: The management team at KWC has been in ?

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

MARCH 29, 2020

o Technology powered research: Virtual clinical trials and other accelerated technologies that mix the potential of new technologies with cannabis to create research insights quickly and more accurately, are being classified as Cannabis 3.0, triggering new innovations and improved data quality through better user experiences.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. For further information: For media inquiries: Contact Jonathan McGuire, Assistant Vice President, Corporate Communications, Horizons ETFs Management (Canada) Inc.,

Data 105

Data Clinical Trials Decriminalization Hemp 105